- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patrick Courneya, MD, Discusses the Policy Implications of Integrated Care Models
Patrick Courneya, MD, CHIE, Health Plan Medical Director, HealthPartners, Inc, says integration is not necessarily a description of a business model, but a description of a care model.
Patrick Courneya, MD, CHIE, Health Plan Medical Director, HealthPartners, Inc, says integration is not necessarily a description of a business model, but a description of a care model. He adds that effective integration of care delivery across different organizations, especially large multispecialty groups, is made possible through efficient communication structures.
Dr Courneya adds that large multispecialty groups must be committed to executing integration, and be willing to subject themselves to public reporting of performance measures. This willingness will help them realize whether or not they are living up to their full potential as a large integrated multispecialty group.
“I’m actually more interested in judging their performance not based on what they’re called, but based on what their results are,” Dr Courneya said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
